Evidence map›Paper›PMID 40908122›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2025

Toward Imaging of the GABA Transporter Type 1 In Vivo: Quantitative Evaluation of 4 Novel PET Radiotracers in Nonhuman Primates.

Paul Gravel, Jiwei Gu, Chao Wang, Tommaso Volpi, Jean-Dominique Gallezot, Daniel Holden, Krista Fowles, Ming-Qiang Zheng, Li Zhang, Edilio Borroni and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Paul GravelPET Center, Department of Radiology and Biomedical Imaging, Yale University, New Haven, Connecticut; paul.gravel@yale.edu.
Jiwei GuPET Center, Department of Radiology and Biomedical Imaging, Yale University, New Haven, Connecticut.
Chao WangPET Center, Department of Radiology and Biomedical Imaging, Yale University, New Haven, Connecticut.
Tommaso VolpiPET Center, Department of Radiology and Biomedical Imaging, Yale University, New Haven, Connecticut.
Jean-Dominique GallezotPET Center, Department of Radiology and Biomedical Imaging, Yale University, New Haven, Connecticut.
Daniel HoldenPET Center, Department of Radiology and Biomedical Imaging, Yale University, New Haven, Connecticut.
Krista FowlesPET Center, Department of Radiology and Biomedical Imaging, Yale University, New Haven, Connecticut.
Ming-Qiang ZhengPET Center, Department of Radiology and Biomedical Imaging, Yale University, New Haven, Connecticut.
Li ZhangPET Center, Department of Radiology and Biomedical Imaging, Yale University, New Haven, Connecticut.
Edilio BorroniPharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland; and.
Michael HonerPharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland; and.
Luca GobbiPharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland; and.
Gilles TamagnanDepartment of Psychiatry, Yale University, New Haven, Connecticut.
Yiyun HuangPET Center, Department of Radiology and Biomedical Imaging, Yale University, New Haven, Connecticut.
Richard E CarsonPET Center, Department of Radiology and Biomedical Imaging, Yale University, New Haven, Connecticut.

Funding

YALE UNIVERSITY CLINICAL AND TRANSLATIONAL SCIENCE AWARD PROGRAMUL1RR024139 · NCRR · YALE UNIVERSITY · PI SHERWIN, ROBERT S · 2006 to 2011
$56.8M
A Program for Innovative PET Radioligand Development and Application - A Translational Toolbox for Treatments for Mental HealthU01MH107803 · NIMH · YALE UNIVERSITY · PI Richard E. Carson, YIYUN HENRY HUANG · 2015 to 2026
$13.7M
NCRR NIH HHS UL1 RR024139NIMH NIH HHS U01 MH107803
6 · The paper itself

Abstract

The main inhibitory neurotransmitter in the central nervous system is γ-aminobutyric acid (GABA). GABA transporter type 1 (GAT-1) is the principal GABA transporter in the brain, and it plays a crucial role in modulating GABA signaling. Its potential role in several neuropsychiatric disorders makes it an important target to study. Although PET radiotracers exist for the GABA receptors, none have been successful for imaging GAT-1. The focus of this work was to evaluate the kinetic behavior of 4 novel

Indexed as

GABA Plasma Membrane Transport ProteinsPositron-Emission TomographyRadiopharmaceuticalsAnimalsBrainFluorine RadioisotopesKineticsMacaca mulattaMaleNipecotic AcidsRadioactive TracersTiagabineTissue DistributionFluorine RadioisotopesGABA Plasma Membrane Transport ProteinsNipecotic AcidsRadioactive TracersRadiopharmaceuticalsTiagabineGABAGAT-1kinetic modelingPET imaging

Identifiers

PMID40908122
PMCPMC12487869

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.